Peptide-polyketide antibiotic from the pathogen that causes American Foulbrood
Infections with American foulbrood can destroy entire bee populations. A team of German and Dutch researchers has now isolated metabolic products of the pathogen that causes it, Paenibacillus larvae. The structures of the products have been identified, providing insights into the unusual biosynthetic pathways by which they are made. These new findings could help to clarify the mechanisms of infection and thus to find points of attack for effectively combating bee disease. As the researchers report in the journal Angewandte Chemie, these paenilamicins have antibiotic effects that may also be of use in human medicine.
The honey bee is one of the most important pollinators in our agricultural and subnatural ecosystems. Our supply with fruit, nuts, and vegetables depends significantly on the fact that enough honey bees fly to the flowers of these plants. In recent years, pesticides and other environmental factors have posed massive health threads to bees. Infectious diseases can cause the death of bee populations. The American foulbrood of bees is a frequently encountered notifiable animal disease which causes infected larvae to essentially disintegrate.
Currently, not enough is known about the molecular mechanisms of the infection to effectively combat this disease. A team at the Technical University of Berlin, the Institute for Bee Research in Hohen Neuendorf, and the University of Leiden (Netherlands) has now gained some new insights: The genome of the pathogen contains genes for an interesting class of natural compounds, peptide-polyketide hybrids with antibacterial and antimycotic effects. The researchers found the special biosynthetic pathways for the formation of these metabolites, which does not use ribosomes, to be fascinating.
The team headed by Roderich Süssmuth and Elke Genersch was able to isolate several of these paenilamicins. They were then able to determine their structures and to characterize their amazing bioactivity: The bacteria release these compounds after they have infected bee larvae in order to keep competitors at bay. Paenibacillus larvae thus effectively kills off the bacterium Paenibacillus alvei in the intestines of the larvae, for example.
The scientists hope that their new insights into the paenilamicins and their biosynthetic pathways will lead to new approaches for combating foulbrood. In addition, the antibiotic effects of these substances could be a starting point for the development of novel human and veterinary pharmaceuticals.
About the Author
Dr Roderich Süssmuth is Professor for Chemical Biology at Technische Universität Berlin. His main specialty is the discovery and biosynthesis investigation of new secondary metabolites from microorganisms and their profiling as antiinfective drugs. He is a Fellow of the Cluster of Excellence “UniCat” coordinated by TU Berlin.
Author: Roderich Süssmuth, Technische Universität Berlin (Germany), http://www.biochemie.tu-berlin.de/
Title: Paenilamicin: Structure and Biosynthesis of a Hybrid Nonribosomal Peptide/Polyketide Antibiotic from the Bee Pathogen Paenibacillus larvae
Angewandte Chemie International Edition, Permalink to the article: http://dx.doi.org/10.1002/anie.201404572
Roderich Süssmuth | Angewandte Chemie
Breaking through a double wall with a sledgehammer
29.06.2015 | Max-Planck-Institut für Entwicklungsbiologie
Lean but sated: Molecular Switch for a Healthy Metabolism discovered
29.06.2015 | Leibniz-Institut für Altersforschung - Fritz-Lipmann-Institut e.V. (FLI)
Think of an object made of iron: An I-beam, a car frame, a nail. Now imagine that half of the iron in that object owes its existence to bacteria living two and a half billion years ago.
Think of an object made of iron: An I-beam, a car frame, a nail. Now imagine that half of the iron in that object owes its existence to bacteria living two and...
A team of scientists including PhD student Friedrich Schuler from the Laboratory of MEMS Applications at the Department of Microsystems Engineering (IMTEK) of...
The three-year clinical trial results of the retinal implant popularly known as the "bionic eye," have proven the long-term efficacy, safety and reliability of...
On June 23, the second Sentinel mission was launched from the space mission launch center in Kourou. A critical component of Aachen is on board. Researchers at the Fraunhofer Institute for Laser Technology ILT and Tesat-Spacecom have jointly developed the know-how for space-qualified laser components. For the Sentinel mission the diode laser pump module of the Laser Communication Terminal LCT was planned and constructed in Aachen in cooperation with the manufacturer of the LCT, Tesat-Spacecom, and the Ferdinand Braun Institute.
After eight years of preparation, in the early morning of June 23 the time had come: in Kourou in French Guiana, the European Space Agency launched the...
(Nano)islands that slide freely on a sea of copper, but when they become too large (and too dense) they end up getting stuck: that nicely sums up the system...
25.06.2015 | Event News
16.06.2015 | Event News
11.06.2015 | Event News
29.06.2015 | Life Sciences
29.06.2015 | Life Sciences
29.06.2015 | Physics and Astronomy